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CF = cystic fibrosis; COPD = chronic obstructive pulmonary disease; FGF = fibroblast growth factor; IGF = insulin-like growth factor; MCP =
monocyte chemoattractant protein; MMP = matrix metalloproteinase; MT = membrane-type MMP; TGF = transforming growth factor; TIMP = tissue
inhibitor of metalloproteinases; TNF = tumor necrosis factor.
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Introduction
MMPs comprise a large family of extracellular enzymes
that share common structural features, particularly those
regions involved in the regulation of proteolytic activity.
MMPs, or matrixins, are a subgroup of the much larger
metalloproteinase superfamily, which also includes
astacin, ADAM, and ADAMTS proteinases, among others
[1,2]. Twenty-three different vertebrate MMPs have been
cloned to date (Table 1), and additional members continue
to be identified.
Numerous studies have assessed the mechanisms con-
trolling MMP expression in lung tissue and lung-derived
cells, and to localize the sites of enzyme expression in
various diseases. We will not summarize everything that is
known about MMPs in the lung, as there are simply too
many papers to summarize in a succinct review. We shall
instead discuss general and emerging concepts of MMP
biology. We will also summarize work on two enzymes,
matrilysin and macrophage metalloelastase, as examples
of how MMPs can function either beneficially in lung repair
or destructively in lung disease.
General features of MMPs
To be classified as a MMP, a protein must have at least
two conserved motifs, namely the pro-domain and the cat-
alytic domain. The pro-domain of a typical MMP is about
80 amino acids, and all MMPs, except MMP-21 and CA-
MMP [3], contain the consensus sequence PRCXXPD.
The catalytic domain contains an active site, Zn2+, that
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binds three conserved histidines in the sequence
HEXXHXXGXXHS/TXXXXXXM, which also contains a
conserved methionine to the carboxy side of the zinc-
binding site. In the inactive state, the conserved cysteine
residue in the pro-domain provides the fourth coordination
site for the catalytic zinc ion, and disruption of this bond is
necessary for enzyme activity.
In addition to the two conserved regions, MMPs have a
variety of specialized domains that contribute to substrate
specificity and recognition or interaction with other pro-
teins or molecules. With the exception of matrilysin,
CA-MMP, and endometase/matrilysin-2 [3–7], MMPs
have a hinge region, which is often proline rich, and a
hemopexin-like C-terminal domain. Four of the six mem-
brane-type MMPs (MT1, MT2, MT3, and MT5) have trans-
membrane and cytosolic domains, whereas MT4-MMP
and leukolysin (MT6-MMP) also have C-terminal hydropho-
bic extensions that act as a glycosylphosphatidylinositol
anchoring signal [3,8,9]. The two gelatinases (MMP-2 and
MMP-9) have gelatin-binding domains, and CA-MMP has
a novel cysteine array motif and an immunoglobulin-like
C2-type fold domain [3,10]. MMPs also share a similar
gene arrangement, suggesting that they were generated
by duplications of an ancestor gene. At least eight of the
known human MMP genes (MMP-1, MMP-3, MMP-7,
MMP-8, MMP-10, MMP-12, MMP-13, and MMP-20) are
clustered on chromosome 11 at 11q21–23 [11•]. Other
known MMP genes are scattered along chromosomes 1,
8, 12, 14, 16, 20, and 22.
Many of the secreted MMPs, such as collagenase-1 and -3,
stromelysins 1, 2, and 3, and gelatinase-B, are not
expressed in normal, healthy, resting tissues or their produc-
tion and activity are maintained at nearly undetectable
levels. In contrast, some level of MMP expression is seen in
any repair or remodeling process, in any diseased or
inflamed tissue, and in essentially any cell type grown in
culture. Although the qualitative pattern and quantitative
levels of MMPs vary among tissues, diseases, tumors,
inflammatory conditions, and cell lines, a reasonably safe
generalization is that activated cells express MMPs. This is
neither a controversial nor a surprising conclusion. After all,
in inflammation, cancer, repair, and other remodeling
processes, the matrix is turned over, cells are migrating, and
secreted factors are processed, and these, among other
events, are the functions attributed to MMPs. Some MMPs,
including matrilysin, endometase/matrilysin-2, leukolysin,
MT5-MMP, and MMP-19, are expressed in healthy tissues
[7,12–14], implying roles in tissue homeostasis.
Functions and substrates
As their name suggests, MMPs are thought to be respon-
sible for the turnover and degradation of connective tissue
proteins, a function that is clearly performed by several
family members. Indeed, cancer patients (including some
with lung carcinomas) enrolled in clinical studies to assess
the chemotherapeutic effects of a broad-acting synthetic
metalloproteinase inhibitor developed reversible skin thick-
ening and joint contractures [15,16]. These sclerotic side
effects have been interpreted to indicate that some MMPs,
directly or indirectly, are required for the normal catalysis
of connective tissue. Although numerous biochemical
studies have demonstrated that almost all MMPs can
cleave or degrade some protein component(s) of the
extracellular matrix, an ability to act on connective tissue
protein is not a requirement for membership into the matrix
metalloproteinase family. For example, human stromelysin-
3 and CA-MMP have no known extracellular matrix sub-
strates [3,17]. As for most protein families, structural
Table 1
Matrix metalloproteinases (MMPs)
MMP designation* Common name (other or previous names)
MMP-1 Collagenase-1 (fibroblast collagenase, interstitial 
collagenase)
MMP-2 Gelatinase-A (72 kDa gelatinase, 72 kDa type IV 
collagenase)
MMP-3 Stromelysin-1 (transin-1)
MMP-7 Matrilysin (PUMP)
MMP-8 Collagenase-2 (neutrophil collagenase)
MMP-9 Gelatinase-B (92 kDa gelatinase, 92 kDa type IV 
collagenase)
MMP-10 Stromelysin-2 (transin-2)
MMP-11 Stromelysin-3
MMP-12 Macrophage metalloelastase
MMP-13 Collagenase-3 (rat collagenase)
MMP-14 MT1-MMP (membrane-type MMP)
MMP-15 MT2-MMP
MMP-16 MT3-MMP
MMP-17 MT4-MMP
MMP-18 Collagenase-4†
MMP-19
MMP-20 Enamelysin
MMP-21
MMP-22
MMP-23 CA-MMP
MMP-24 MT5-MMP
MMP-25 Leukolysin (MT6-MMP)
MMP-26 Endometase (matrilysin-2)
*There is no MMP-4, MMP-5, or MMP-6. After matrilysin was
discovered and designated as MMP-7, MMP-4 to MMP-6 were
determined to be either MMP-2 or MMP-3. †Collagenase-4 was
isolated from Xenopus. A mammalian homolog has not been found.Respiratory Research    Vol 2 No 1 Parks and Shapiro
features are thus more relevant than a presumed common
activity in assigning members to this family [18••].
It is becoming increasingly clear that matrix degradation is
neither the sole nor common function of these enzymes
[18••]. MMPs are, after all, proteinases, and most pro-
teinases can act on a wide variety of proteins. Indeed,
several reports from past years have suggested or demon-
strated that various MMPs can modulate the activity of a
variety of non-matrix proteins. For example, matrilysin acti-
vates the pro-form of a-defensins [19••], a class of
secreted antimicrobial peptides (see later), and various
MMPs can inactivate the serpin a1-antiproteinase inhibitor
[20,21,22••]. Several MMPs, such as collagenase-1,
gelatinase-A, stromelysin-1, matrilysin, and stromelysin-3,
among others, directly modulate the activity of several
growth factors and chemokines, such as transforming
growth factor (TGF)-b1, tumor necrosis factor (TNF)-a,
insulin-like growth factor (IGF)-1, epidermal growth
factors, fibroblast growth factors (FGFs), and monocyte
chemoattractant protein (MCP)-3 [23•,24–28,29•]. In
addition, fragments of matrix proteins released by MMP-
mediated proteolysis can act as chemoattractants for
distant cells. MMPs should thus not be viewed solely as
proteinases of matrix catalysis, but as extracellular pro-
cessing enzymes critically involved in cell–cell and
cell–matrix signaling.
The use of genetically defined animal models has allowed
investigators to uncover specific and, at times, unexpected
functions of MMPs (Table 2). All of the MMPs targeted to
date (Table 2), except MT1-MMP, show no or only a minor
phenotype in unchallenged mice, indicating that these
enzymes do not serve vital functions in development or
homeostasis. The responses of MMP knockout mice to a
variety of challenges, in contrast, indicate that these
enzymes do serve specific roles in tissue repair, immunity,
angiogenesis, host defense, inflammation, and tumor pro-
gression, among others (Table 2). It thus seems that
several MMPs, at least those that have been knocked out,
have evolved to respond to the many insults we experi-
ence in our extra-uterine existence.
Table 2
Phenotype of matrix metalloproteinase (MMP) knockout mice
Phenotype
Gene Lethal Unchallenged Challenged*
Gelatinase-A (MMP-2) No • None [56] •  Reduction in angiogenesis and tumor growth [57]
Stromelysin-1 (MMP-3) No • None [58] •  Impaired wound contraction [59]
•  Reduced contact hypersensitivity response [60]
•  Accelerated arthritis [58]
Matrilysin (MMP-7) No • Lack of activated antimicrobial peptides [19••] 3 Inability to repair mucosal epithelial wounds [39••]
•  Reduced ability to kill pathogenic bacteria [19••]
•  Reduced tumorigenesis [61]
Gelatinase-B (MMP-9) No • Transient slowing of long bone growth  3 Normal neutrophil extravasation [63•]
secondary to reduced angiogenesis [62] 3 Lack of alveolar brochiolization in fibrosis [45•]
•  Resistant to induced blister formation [22••,64]
•  Persistent contact hypersensitivity response [60]
•  Protection against aortic aneurysm formation [65]
•  Reduced ventricular enlargement and rupture 
postmyocardial infarction [66,67]
•  Delayed tumor progression and reduced metastases [68]
Stromelysin-3 (MMP-11) No • None [69] •  Less chemically induced tumors and reduced tumor 
cell implantation [69]
• Accelerated and enhanced neointimal formation [70]
Macrophage  No • None [53] 3 Reduced elastolytic capacity of macrophages [53]
metalloelastase (MMP-12) 3 Protection against smoking-induced 
emphysema [54••]
•  Reduced ability of macrophages to migrate through 
matrix [53]
MT1-MMP (MMP-14) Yes • Severe skeletal abnormalities [71•] •  Not yet assessed
*3, Assessed in lung.As for all secreted proteinases, the catalytic activity of
MMPs is regulated at four points — gene expression, com-
partmentalization, enzyme activation, and enzyme inactiva-
tion — and is further controlled by substrate availability and
affinities. Although each MMP is often described as having
a limited substrate specificity, individual enzymes can act
on many different proteins, and the spectrum of substrates
among many enzymes is actually quite similar. For example,
gelatinase-A, gelatinase-B, stromelysin-1, stromelysin-2,
matrilysin, macrophage metalloelastase, and collagenase-3
can each degrade non-fibrillar collagens, basement mem-
brane components, fibrillins, fibronectin, and more. Distinct
from other MMPs, collagenase-1 and collagenase-2 seem
to have a very defined substrate spectrum, being limited to
the fibrillar collagens, types I, II, and III. Aside from the colla-
genases, the set of substrates that overlap among MMPs is
more impressive than that of selective substrates.
In a setting such as inflammation, in which essentially all
MMPs are present, the shared substrate potential among
enzymes would seemingly permit biochemical redundancy.
Two processes, however, can hone substrate selectivity:
enzyme affinity and compartmentalization. Kinetic studies
have demonstrated that specific enzymes degrade some
substrates more efficiently than others. For example, both
gelatinase-A and gelatinase-B act on cleaved collagen
better than other MMPs [30], matrilysin is a more potent
proteoglycanse than stromelysin-1 or gelatinase-B [31],
macrophage metalloelastase is the most elastolytic
enzyme of the MMP family [32], and only the collagenases
can cleave native fibrillar collagens. In a complex tissue
environment, which contains many types of matrix proteins
and many other potential substrates, selectivity of MMP
catalysis may thus be directed, in part, by the concentra-
tion of a preferred substrate relative to that of other poten-
tial substrates within range of a secreted MMP.
Compartmentalization
Where in the tissue environment and by which cells a
MMP is expressed and released are equally, if not more
important, considerations in regulating the specificity of
proteolysis than the affinity of the enzyme–substrate inter-
action. For example, in a test tube, matrilysin inactivates
a1-antiproteinase inhibitor much more efficiently than does
gelatinase-B. However, in tissue, at least in inflamed
dermis, this serpin is selectively cleaved by neutrophil-
derived gelatinase-B [22••]. Matrilysin, an epithelial cell
product, tends to be released lumenally away from the
matrix (see later). An important concept is that cells do not
indiscriminately release proteases. Rather, proteinases,
such as MMPs, are secreted and anchored to the cell
membrane, thereby targeting their catalytic activity to spe-
cific substrates within the pericellular space. Specific
cell–MMP interactions have been reported in recent years,
such as the binding of gelatinase-A to the integrin avb3
[33], binding of gelatinase-B to CD44 [28], and binding of
matrilysin to surface proteoglycans [34]. Pro-gelatinase-A
also interacts with tissue inhibitor of metalloproteinases
(TIMP)-2 and MT1-MMP on the cell surface, and this
trimeric complex is essential for activation of this gelati-
nase [35,36]. It is likely that other MMPs are also attached
to cells via specific interaction to membrane proteins, and
determining these anchors will lead to identifying activa-
tion mechanisms and pericellular substrates.
Cells also rely on surface receptors to ‘sniff out’ the pres-
ence and location of specific substrates. For matrix sub-
strates, integrin–ligand contacts provide an unambiguous
signal informing the cell of which protein it has encoun-
tered and, hence, which proteinase is needed and to
where the enzyme should be delivered and released. A
clear example of this type of spatial regulation is seen with
collagenase-1 in human cutaneous wounds. Collagenase-
1 is induced in basal epidermal cells (keratinocytes), in
response to injury, as the cells move off the basement
membrane and contact type I collagen in the underlying
dermis [37]. Only basal keratinocytes in contact with
dermal type I collagen express collagenase-1, and this
inductive response is specifically controlled by the colla-
gen-binding integrin a2b1, which also directs secretion of
the enzyme to the points of cell–matrix contact [38]. This
example demonstrates that expression and activity of a
specific MMP can be confined to a specific location in an
activated tissue (the superficial plane of a denuded epithe-
lium) and to a specific stage of repair (re-epithelialization).
Matrilysin
As already stated, matrilysin, the smallest (28 kDa) of the
known MMPs, is expressed by non-injured, non-inflamed
exocrine and mucosal epithelium in most, if not all, adult
tissues. In adult human lung, whether normal or diseased,
matrilysin is expressed by epithelial cells lining peri-
bronchial glands and conducting airways [39••]. The
expression of matrilysin in non-injured, normal epithelium
suggests that this enzyme serves a common homeostatic
function among epithelia, and several observations impli-
cate a role for matrilysin in innate immunity among epithe-
lia. All tissues in which matrilysin is ‘constitutively’
expressed are open to the environment and, hence, are
vulnerable to bacterial exposure, and matrilysin is promi-
nently upregulated in tissues with a heavy bacterial load,
such as in lungs with cystic fibrosis (CF) (see later). Both
immunohistochemical and cell culture studies have also
demonstrated that the matrilysin protein produced by non-
injured epithelium is released into the airway lumen
[39••,40•], indicating that this MMP acts on non-matrix
substrates. Indeed, matrilysin is responsible for the activa-
tion of prodefensins in the small intestine [19••].
A common role of the mucosal epithelium is to function as
an active barrier against the external environment, and the
secretion of antibiotic peptides by epithelial cells appears
Available online http://respiratory-research.com/content/2/1/010
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and b-defensins comprise a family of cationic peptides that
kill bacteria by membrane disruption [41]. The pro-segment
of  a-defensin precursors maintains them in an inactive
state, and proteolysis at some point in the secretion
pathway is needed to remove the pro-domain. In the mouse
small intestine, matrilysin is co-expressed and co-sorted
with pro-a-defensins in Paneth cells, which are specialized
epithelial cells that secrete defensins and other antimicro-
bial molecules, and this intimate compartmentalization of
proteinase and potential substrate suggests that matrilysin
activates these peptides in the secretion pathway. Indeed,
in matrilysin knockout mice, pro-a-defensins are not
processed to their active forms by matrilysin, and defi-
ciency of this enzyme results in impaired bacteriocidal
activity in vitro and in vivo [19••]. Because of a lack of
defensin activation, matrilysin null mice cannot effectively
kill pathogenic Escherichia coli and are themselves killed
by doses of Salmonella typhimurium that are not lethal to
wild-type mice. Matrilysin thus functions in mucosal immu-
nity by regulating the activity antimicrobial peptides, a func-
tion that this MMP may also serve in the lung.
Because of the role of matrilysin in innate defense, it
became reasonable to hypothesize that the interaction of
bacteria with host cells regulates enzyme expression. Bac-
teria are, after all, an indirect ‘substrate’ of matrilysin, and
the presence of substrates often regulates MMP produc-
tion. Indeed, matrilysin is strongly induced (>50-fold) in
human and murine mucosal epithelial tissues, including
intact human and mouse airway, by bacterial exposure
[40•]. This induction is remarkably potent and sensitive,
requiring relatively short exposure and less than 10 bacte-
ria per epithelial cell in the initial inoculum, and is not medi-
ated by lipopolysaccharide. Large amounts of matrilysin
protein, in both its zymogen and activated forms, are
released from infected airway epithelial cells and from
normal human trachea (Fig. 1). In addition, bacteria-medi-
ated stimulation of matrilysin is restricted to mucosal
epithelial cells. Bacterial exposure does not affect the
expression of other MMPs examined and does not influ-
ence matrilysin expression in other cell types, namely
macrophages, fibroblasts, and keratinocytes.
The widespread production of matrilysin in conducting
airway epithelium may be initially induced and subsequently
sustained by continual, low-level bacterial exposure. Con-
sistent with this idea, matrilysin is seen in adult tissues but
is not detected in developed glandular epithelium in utero
[42] or in fetal or perinatal mouse tissues [43]. Further-
more, matrilysin is not produced at detectable levels in
adult germ-free mice but is expressed in mice with a con-
ventional microflora and in exgerm-free mice colonized with
just one species of commensal bacteria [40•]. Bacterial
exposure thus seems to be the physiologic signal that reg-
ulates matrilysin expression in intact epithelium.
Although matrilysin is clearly regulated by bacterial expo-
sure, it is possible that production of this enzyme is also
induced in response to injury. Because injury provides an
opportunity for infection and infection can lead to injury,
some of the epithelial responses associated with either of
these events may actually be a key component of both
responses. Expression of matrilysin is indeed seen in
airway and alveolar epithelial cells at sites of overt damage
in emphysema, in fibrotic lungs with diffuse alveolar
damage, in inflamed lungs of patients with idiopathic
pneumonia syndrome following bone marrow transplanta-
tion, and most prominently in lungs from patients with CF
[39••]. Because bacterial colonization may be associated
with sites of airway injury, especially in the CF samples, it
was not clear if injury alone can induce matrilysin expres-
sion. A prominent signal for matrilysin protein is, however,
seen in migrating epithelial cells in isolated human tra-
cheas that are injured under aseptic conditions (Fig. 2).
These observations demonstrate that matrilysin is induced
by injury and is prominently expressed by migrating epithe-
lial cells. Although we do not yet know what process or
factor induces matrilysin in epithelial cells at the wound
edge, candidates would include a loss of specific cell–cell
Respiratory Research    Vol 2 No 1 Parks and Shapiro
Figure 1
Ex vivo infection of human tracheal explants and infection of human
tracheal epithelial cells. (a) Pieces (1 cm3) of freshly isolated normal
adult human trachea were infected with the Escherichia coli isolates
NU14 (fimH+) and NU14-1 (fimH–) for 90 min and incubated for 24 h
in fresh media containing 50 mg/ml gentamicin as previously described
[40•]. NU14 is an E. coli strain isolated from a patient with cystitis and
expresses FimH-containing type 1 pili. NU14-1 is a fimH– mutant in
which a chloramphenicol cassette was recombined into the fimH gene
in the chromosome of NU14 [25]. FimH is a mannose-binding adhesin
that mediates the interaction of type 1-piliated bacteria with mannose-
containing glycoproteins on eukaryotic cell surfaces. Released and
activated matrilysin was detected by western analysis. (b) Human
tracheal primary epithelial cells were infected with the type 1 piliated
recombinant strains ORN103/pSH2 (fimH+) and ORN103/pUT2002
(fimH–) for 90 min, and allowed to condition fresh media for 48 h.
Matrilysin secretion was assessed by immunoblotting. (Reproduced
from [40•]; copyright permission of The Rockefeller University Press.)contacts, changes in cytoskeleton, or establishment of new
cell–matrix interactions. Furthermore, in the absence of bac-
teria, wound-induced matrilysin is released basally towards
the underlying matrix, suggesting that matrilysin may facili-
tate cell migration by acting on an extracellular protein. The
regulated, vectorial release (ie compartmentalization) of a
MMP would thus allow the proteinase to act on spatial dis-
tinct substrates, thereby serving different functions.
A functional role for matrilysin in airway re-epithelialization
was demonstrated by repair of injured tracheas from gene-
targeted mice [39••]. As in human tissue, matrilysin is
expressed in airway epithelial cells that had migrated over
the cut edges of dissected mouse tracheas [39••]. In tra-
cheas from wild-type mice, re-epithelialization progresses
rapidly; however, wounds in tracheas from matrilysin null
mice show no evidence of epithelial migration. Matrilysin-
deficient mice have in fact shown the most severe wound-
repair defect among the MMP knockout mice generated to
date (Table 2). However, the mechanism of how matrilysin
facilities repair is not known. It may be required to loosen
cell–matrix and cell–cell contacts, as has been suggested
for other MMPs in other epithelial repair/migration models
[38,44•]. Furthermore, matrilysin may not be the only MMP
involved in repair of airway epithelial wounds. Gelatinase-
B is also expressed by injured epithelial cells in distal
airways, in response to bleomycin instillation, and defi-
ciency of this MMP leads to excessive bronchiolization
[45•], suggesting a role in either cell migration or differen-
tiation. In addition, Legrand et al have demonstrated that
the activity of gelatinase-B is required for the migration of
isolated airway epithelial cells over a matrix substratum
[46]. Several MMPs may thus act concurrently on different
substrates to facilitate repair. These observations also
demonstrate important reparative roles for MMPs but, as
is discussed later, overexpression or chronic expression of
proteinases may lead to tissue damage.
Macrophage metalloelastase
The progressive structural damage associated with
emphysema and other forms of chronic obstructive pul-
monary disease (COPD) is due to degradation of selective
extracellular matrix components. To determine which pro-
teinases are involved in the development of COPD, one
must focus on proteinases that can degrade elastin, a
highly proteinase-resistant polymer that normally lasts the
human lifespan [47]. The elastin content of the lung
parenchyma is decreased in emphysema, while the colla-
gen content is increased [48]. Some studies have pro-
posed that collagenases, such as collagenase-1,
contribute to airway enlargement [49], but the accumula-
tion of collagen at sites of emphysematous damage
strongly indicates that lung collagenases are acting else-
where. Elastic fibers in the emphysematous lung are ultra-
structurally disorganized and fragmented. Instillation of
elastases, but not collagenases, into the lungs of experi-
mental animals causes emphysema, further implicating
elastolytic enzymes in human disease.
Several MMPs are produced in human emphysematous
lung [50,51]. Furthermore, several studies using trans-
genic and gene-targeted mice lend support to the role of
MMPs in emphysema. For example, induced overexpres-
sion of IL-13 results in production of several MMPs,
leading to emphysema [52]. Among these MMPs, metal-
loelastase was a reasonably guilty culprit in the break-
down of alveolar elastin. As already mentioned, this
enzyme is a potent elastase, and macrophages from met-
alloelastase null mice cannot degrade elastin or many
other matrix substrates [53].
Exposing proteinase null mice to cigarette smoke provides a
highly controlled model to assess the role of specific MMPs
in emphysema. Long-term exposure of wild-type mice to cig-
arette smoke leads to inflammatory cell recruitment followed
by alveolar space enlargement that is quite similar to the
lesions that develop in humans. Mice deficient in metalloe-
lastase, however, are markedly protected from development
of emphysema due to long-term smoke exposure [54••].
Interestingly, metalloelastase null mice failed to recruit
monocytes into their lungs in response to cigarette smoke.
Because metalloelastase and most other MMPs are only
expressed upon differentiation of monocytes to
macrophages, it appeared unlikely that monocytes require
metalloelastase for transvascular migration. Cigarette
smoke may thus induce constitutive macrophages, which
are present in lungs of metalloelastase knockout mice, to
Available online http://respiratory-research.com/content/2/1/010
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Figure 2
Expression of matrilysin in injured tracheal explants. Sections of a
segment of normal human trachea were incubated in culture medium at
37°C for 5 days (d5) before fixation and immunohistochemistry for
matrilysin protein [39••]. The edge of the biopsy and the margin of
basement membrane, which is the clear area underlying the epithelium,
is marked by the large arrow. By 5 days postplating, the epithelial cells
have migrated progressively and intense staining for matrilysin is
observed in these migrating cells, especially those in close contact with
the underlying matrix. Release of matrilysin towards the matrix was seen
in association with some cells (small arrows). No signal was seen in
sections processed with preimmune serum (PI). Bar = 20 mm.
(Reproduced from [39••]; copyright permission of The American Society
for Clinical Investigation.)produce metalloelastase that in turn cleaves elastin, thereby
generating fragments chemotactic for monocytes. This posi-
tive feedback loop would perpetuate macrophage accumu-
lation, leading to progressive and chronic lung destruction.
Consistent with this idea, experiments performed more than
20 years ago by Senior et al demonstrated that proteolyti-
cally generated elastin fragments mediate monocyte
chemotaxis [55]. Gene targeting is merely reinforcing this as
a major in vivo mechanism of macrophage accumulation in
a chronic inflammatory condition.
There are probably several proteinases and inflammatory
cells involved in the development of emphysema in
humans. The major lesson to be gained from murine
models of cigarette smoke-induced emphysema is not that
metalloelastase is the sole proteinase responsible for
human disease, but that macrophages have the capacity
to cause emphysema upon recruitment and activation by
cigarette smoke. The predominant macrophage proteinase
in mice is metalloelastase; human macrophages probably
have a broader spectrum of MMPs (including metallo-
elastase). Collagenase-1, -2, and -3 also undoubtedly con-
tribute to loss of the airspace; yet, in the small airspace,
collagen deposition predominates, leading to airway
obstruction complicating simple categorization of collage-
nases as ‘bad guys’.
Moreover, multiple enzymes from different families may
cooperate in tissue remodeling at the same time and place.
For example, metalloelastase, as well as other MMPs,
degrades a1-antiproteinase inhibitor, and neutrophil elas-
tase, a serine proteinase, degrades TIMPs. These enzymes,
by neutralizing each other’s natural inhibitors, can thus
amplify overall proteolytic activity. This concept was shown
in vivo in studies by Liu et al [22••]. They demonstrated,
using a murine model of bullous pemphigoid, that skin blis-
ters form as a result of neutrophil MMP-9 degrading a1-
antiproteinase inhibitor, thus allowing unopposed
neutrophil elastase activity, which degrades hemidesmoso-
mal proteins. We have not been able to determine a role for
MMP-9 in emphysema; however, metalloelastase degrades
a1-antiproteinase inhibitor, in part explaining why metalloe-
lastase mice are totally protected from smoke-induced
emphysema, whereas neutrophil elastase mice are only
partially protected.
Conclusion
Several studies have shown that excessive levels of many
MMPs are present in chronically inflamed tissues through-
out the body. These observations have led to the often
held concept that excessive proteolysis damages tissues
and impairs healing. Unregulated, excessive proteolysis is
indeed probably responsible for the destruction of matrix
proteins in emphysema, as well as in arthritis, aneurysms,
and other conditions of structural tissues. It seems pre-
sumptuous, however, to conclude that all proteinases
expressed in diseased tissue contribute to disease patho-
genesis. Based on the mechanisms uncovered in
matrilysin and MMP-9 null mice, expression of these
MMPs in injured airway cells may reflect beneficial roles in
re-epithelialization and mucosal defense against bacteria.
Because MMPs can both breakdown and activate pro-
teins, we cannot conclude by their presence alone
whether a specific proteinase in an inflammatory or injury
setting is contributing to a reparative or disease process.
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